CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma.
Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们研究了131名多发性骨髓瘤（MM）患者中EB病毒（EBV）和巨细胞病毒（CMV）感染的发生率，其中53名接受达雷妥尤单抗（Dara）治疗。与未接受Dara的组相比，Dara组复发/难治性MM患者更多。Dara治疗患者CMV感染显著更常见（16.98%），未接受Dara方案治疗者为2.56%。Dara治疗期间，24.53%的患者发生CMV和/或EBV感染。发生感染的患者外周血白蛋白和淋巴细胞水平显著较低。从首次Dara输注到感染的中位时间为27天。我们观察到Dara治疗期间NK细胞减少、T细胞扩增。与未感染患者相比，发生CMV和/或EBV感染者在首次Dara输注后1个月的NK细胞、总T细胞和CD8⁺ T细胞数量显著较低；2个月时CD8⁺ T细胞数量仍较低。
ABSTRACTSWe explored the incidence of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections in 131 patients with multiple myeloma (MM), 53 of whom received daratumumab (Dara) treatments. The Dara group had more RRMM patients than the group without Dara. CMV infection was significantly more common in patients treated with Dara (16.
98%) than in patients treated with regimens without Dara (2. 56%). During Dara treatments, 24. 53% of patients developed CMV and/or EBV infections. Patients who developed infections had significantly lower levels of albumin and lymphocytes in their peripheral blood. The median time from the first Dara infusion to infection was 27 days.
We observed NK cell depletion and T cell expansion during Dara-treatment. Patients with CMV and/or EBV infections had significantly lower numbers of NK cells, total T cells, and CD8 + T cells at 1 month, and lower numbers of CD8 + T cells at 2 months after the first Dara infusion than those without infections.
MEMBER ACCOUNT
登录成功会直接打开下一页。
